Company: RGNX
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0000950170-25-038770
Chunk: 67

Company: REGENXBIO Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 16
Chunk 67
---
 the consolidated financial information regularly provided to the CODM. The CODM reviews and evaluates consolidated net income (loss) for purposes of assessing performance, making operating decisions and allocating resources. The CODM uses net income (loss) to assess performance versus operating budgets and in the preparation of near-term and long-range operating plans to inform decisions on resource and capital allocation. The CODM reviews consolidated cash, cash equivalents and marketable securities as a measure of segment assets. As of December 31, 2024 and 2023, the Company’s cash, cash equivalents and marketable securities were $244.9 million and $314.1 million, respectively.

125

The following table presents information about the Company's segment revenues, significant segment expenses regularly provided to the CODM, other segment items and consolidated net income (loss) (in thousands): 

        Years Ended December 31,

        2024

        2023

        2022

        Revenues
         
        $
        83,328

        $
        90,242

        $
        112,724

        Less:

        Cost of revenues

        33,567

        37,213

        54,545

        Research and development expense

        Personnel

        65,950

        73,356

        67,466

        Direct development and support (a)

        97,951

        110,337

        131,397

        Facilities

        11,410

        11,653

        10,284

        Stock-based compensation

        17,985

        20,568

        21,368

        Depreciation and amortization

        15,226

        16,352

        11,938

        Total research and development expense

        208,522

        232,266

        242,453

        General and administrative expense

        Personnel

        20,816

        22,304

        21,270

        Other general and administrative (b)

        29,480

        41,609

        40,340

        Facilities

        4,856

        3,914

        3,280

        Stock-based compensation

        20,478

        19,699

        19,420

        Depreciation and amortization

        989

        968